SRRK
HEALTHCAREScholar Rock Holding Corp
$47.11-0.03 (-0.05%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving SRRK Today?
No stock-specific AI insight has been generated for SRRK yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$27.07$51.62
$47.11
Fundamentals
Market Cap$5.5B
P/E Ratio—
EPS$-3.29
Dividend Yield—
Dividend / Share—
ROE-1.2%
Profit Margin—
Debt / Equity—
Trading
Volume921K
Avg Volume (10D)—
Shares Outstanding119.3M
SRRK News
21 articles- Scholar Rock Q1 Earnings Call HighlightsMarketbeat·May 9, 2026
- SRRK Maintained by Barclays -- Price Target Raised to $55GuruFocus·May 8, 2026
- Scholar Rock (SRRK) Q1 2026 Earnings TranscriptMotley Fool·May 8, 2026
- A Look At Scholar Rock (SRRK) Valuation After Strong Multi Year Shareholder ReturnsYahoo Finance·May 8, 2026
- Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business HighlightsYahoo Finance·May 7, 2026
- Scholar Rock to Present at the BofA Securities 2026 Health Care ConferenceYahoo Finance·Apr 29, 2026
- Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Apr 17, 2026
- Scholar Rock to Report First Quarter 2026 Financial Results on May 7, 2026Yahoo Finance·Apr 16, 2026
- Scholar Rock (SRRK) Deepens SMA Manufacturing Footprint: Strategic Resilience Move or Regulatory Risk Signal?Yahoo Finance·Apr 6, 2026
- SRRK Stock Jumps on Resubmission of FDA Filing for SMA DrugYahoo Finance·Apr 1, 2026
- Scholar Rock Resubmits Apitegromab BLA for SMA, Adds Second Fill-Finish Site; FDA Decision Eyed by Sept.Marketbeat·Apr 1, 2026
- Correction: Sector Update: Health Care Stocks Advance Premarket TuesdayYahoo Finance·Mar 31, 2026
- Sector Update: Health Care Stocks Advance Premarket TuesdayYahoo Finance·Mar 31, 2026
- Scholar Rock Resubmits Biologics License Application (BLA) to FDA for Apitegromab for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)Yahoo Finance·Mar 31, 2026
- A Look At Scholar Rock Holding (SRRK) Valuation As Growth Expectations Face Mixed Share Price SignalsYahoo Finance·Mar 29, 2026
- Scholar Rock Holding Corporation Q4 2025 Earnings Call SummaryMoby·Mar 4, 2026
- CORRECTING and REPLACING Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business HighlightsYahoo Finance·Mar 3, 2026
- Scholar Rock Q4 Earnings Call HighlightsMarketbeat·Mar 3, 2026
- Assessing Scholar Rock (SRRK) Valuation After Recent Share Pullback And Conflicting P/B And DCF SignalsYahoo Finance·Feb 24, 2026
- Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 MillionMotley Fool·Feb 22, 2026
- Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120%Motley Fool·Feb 22, 2026
All 21 articles loaded
Price Data
Open$47.14
Previous Close$47.14
Day High$48.03
Day Low$46.42
52 Week High$51.62
52 Week Low$27.07
52-Week Range
$27.07$51.62
$47.11
Fundamentals
Market Cap$5.5B
P/E Ratio—
EPS$-3.29
Dividend Yield—
Dividend / Share—
ROE-1.2%
Profit Margin—
Debt / Equity—
Trading
Volume921K
Avg Volume (10D)—
Shares Outstanding119.3M
About Scholar Rock Holding Corp
Scholar Rock Holding Corporation, a clinical-phase biopharmaceutical company, is focused on the discovery and development of drugs for the treatment of serious diseases in which protein growth factor signaling plays a critical role. The company is headquartered in Cambridge, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—